Lonitoclax
Latest Information Update: 06 Nov 2024
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia
Most Recent Events
- 04 Nov 2024 Pharmacodynamics data from preclinical trial in Acute myeloid leukaemia and Chronic lymphocytic leukaemia released by Eilean Therapeutics
- 15 Oct 2024 The US FDA clears IND application for a phase I trial for Chronic lymphocytic leukaemia and Lymphoma
- 04 Oct 2024 Phase-I clinical trials in Acute myeloid leukaemia (unspecified route) before October 2024 (Eilean Therapeutics pipeline, October 2024)